Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 179

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Differential alterations in 5α‐reductase type 1 and type 2 levels during development and progression of prostate cancer

Thomas, Lynn N., Lazier, C.B., Gupta, R., Norman, R.W., Troyer, D.A., O'Brien, S.P., Rittmaster, R.S.·2005·The Prostate

Abstract

BACKGROUND: In the prostate, conversion of testosterone to dihydrotestosterone (DHT), by the enzymes 5α‐reductase types 1 and 2 (5αR1, 5αR2) is required for normal growth and probably also for development of prostate cancer (PCa). Finasteride, a 5αR2 inhibitor, was shown to reduce the prevalence of PCa in the Prostate Cancer Prevention Trial. However, inhibition of both 5αR isoenzymes causes a greater decrease in serum DHT. The aim of this study was to assess differential expression of these enzymes at various stages of PCa development. METHODS: Immunostaining for 5αR1 and 5αR2, using specific, well‐validated antibodies, was evaluated in 26 benign prostatic hyperplasia (BPH) (16 for 5αR2), 53 primary PCa (21 for 5αR2), 18 prostatic intraepithelial neoplasia (PIN), 12 primary PCa treated with neoadjuvant androgen ablation, 15 locally recurrent PCa specimens, and 18 PCa metastases. RESULTS: The mean area of moderate plus high intensity staining for 5αR1 increased from 4.8 ± 2.8% of total epithelial area in BPH, to 18.9 ± 5.7% in PIN, 17.0 ± 3.2% in primary cancer, 38.0 ± 7.3% in recurrent cancer, and 55.8 ± 8.5% in PCa metastases. The mean staining area for 5αR2 decreased from 58.8 ± 7.2% in BPH, to 21.1 ± 5.5% in PIN and 34.8 ± 6.7% in primary PCa. Staining for 5αR2 was increased in recurrent cancer and PCa metastases compared to primary PCa, at 58.7 ± 5.2% and 69.2 ± 8.7%, respectively. CONCLUSIONS: 5αR1 immunostaining is increased and 5αR2 immunostaining is decreased during development of PCa. In addition, there is increased expression of both 5αR isozymes in recurrent and metastatic cancers, suggesting that both isozymes may be important in the development and progression of PCa. © 2004 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/pros.20188

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 179

Metadata

Authors
Thomas, L. N., Lazier, C. B., Gupta, R., Norman, R. W., Troyer, D. A., O'Brien, S. P., & Rittmaster, R. S.
Venue
The Prostate
Publisher
Wiley
Published
2005-03-24
Volume
63
Issue
3
Pages
231-239
ISSN
  • 0270-4137 (ISSN-L)
  • 1097-0045
OpenAlex
W2040556993
Cited by
179
References
1
FWCI
6.77
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Differential alterations in 5α‐reductase type 1 and type 2 levels during development and progression of prostate cancer. https://app.cochat.ai/papers/10.1002/pros.20188
The paper
Thomas, L. N., Lazier, C. B., Gupta, R., Norman, R. W., Troyer, D. A., O'Brien, S. P., & Rittmaster, R. S. (2005). Differential alterations in 5α‐reductase type 1 and type 2 levels during development and progression of prostate cancer. The Prostate. https://doi.org/10.1002/pros.20188

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.